However, given Sig1R's role in neurologic disorders and ChT‐induced pain [22], any in vivo study on synergistic Sig1R antagonists + Px treatment should incorporate behavioral models for Px‐induced neuropathy (such as mechanical allodynia or thermal hyperalgesia) to provide measures of pain sensitivity and other side effects. The gene discussed is SLC5A7; the disease is nervous system disorder.